Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
All investigated doses met the primary efficacy endpoint defined as a change from baseline in A1C versus placebo after 26 weeks of treatment
Regulatory discussions initiated for empagliflozin, as adjunct to insulin, in type 1 diabetes
Full results pr... Biopharmaceuticals, Endocrinology Boehringer Ingelheim, Eli Lilly, empagliflozin, EASE-2 study, diabetes
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Diabetes | Diabetes Type 1 | Empagliflozin | Endocrinology | Insulin | Jardiance | Pharmaceuticals | Study